Cargando…

Diabetes Monotherapies versus Metformin-Based Combination Therapy for the Treatment of Type 2 Diabetes

Step-wise addition of antihyperglycemic agents (AHA) after the initiation of metformin monotherapy has been the traditional approach for the treatment of type 2 diabetes mellitus (T2DM) world-wide. Emerging evidence increasingly suggests that metformin-based combination therapy, especially with the...

Descripción completa

Detalles Bibliográficos
Autores principales:	Singh, Awadhesh K, Singh, Ritu, Chakraborty, Partha Pratim
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8318007/ https://www.ncbi.nlm.nih.gov/pubmed/34335049 http://dx.doi.org/10.2147/IJGM.S295459

Ejemplares similares

Metformin in gestational diabetes: An emerging contender
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Is metformin ahead in the race as a repurposed host-directed therapy for patients with diabetes and COVID-19?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Metabolic and cardiovascular benefits with combination therapy of SGLT-2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Deciding oral drugs after metformin in type 2 diabetes: An evidence-based approach
por: Singh, Awadhesh Kumar
Publicado: (2014)

Sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors combination therapy in type 2 diabetes: A systematic review of current evidence
por: Singh, Awadhesh Kumar, et al.
Publicado: (2016)

Association of metformin monotherapy or combined therapy with cardiovascular risks in patients with type 2 diabetes mellitus
por: Li, Tian, et al.
Publicado: (2021)

Letter by Awadhesh Kumar Singh Regarding Article, “Cardiovascular Outcomes Comparison of Dipeptidyl Peptidase-4 Inhibitors Versus Sulfonylurea as Add-on Therapy for Type 2 Diabetes Mellitus: A Meta-Analysis”
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Early combination versus initial metformin monotherapy in the management of newly diagnosed type 2 diabetes: An East Asian perspective
por: Ji, Linong, et al.
Publicado: (2020)

Trends in add-on medications following metformin monotherapy for type 2 diabetes
por: Swart, Elizabeth CS, et al.
Publicado: (2022)

Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New-Onset Type 2 Diabetes Mellitus
por: Younas, Amna, et al.
Publicado: (2021)

Non-insulin anti-diabetic agents in patients with type 2 diabetes and COVID-19: A Critical Appraisal of Literature
por: Singh, Awadhesh Kumar, et al.
Publicado: (2021)

Secondary metformin monotherapy failure in individuals with type 2 diabetes mellitus
por: Weiss, Tracey, et al.
Publicado: (2021)

Long-Term Glycaemic Durability of Early Combination Therapy Strategy versus Metformin Monotherapy in Korean Patients with Newly Diagnosed Type 2 Diabetes Mellitus
por: Yoo, Soon-Jib, et al.
Publicado: (2021)

Comparative evaluation of the therapeutic effect of metformin monotherapy with metformin and acupuncture combined therapy on weight loss and insulin sensitivity in diabetic patients
por: Firouzjaei, A, et al.
Publicado: (2016)

Predictors of metformin monotherapy failure in gestational diabetes mellitus
por: Benido Silva, Vânia, et al.
Publicado: (2022)

Comparison of Metformin and Repaglinide Monotherapy in the Treatment of New Onset Type 2 Diabetes Mellitus in China
por: Ma, J., et al.
Publicado: (2014)

Effects of a Combination of Empagliflozin Plus Metformin vs. Metformin Monotherapy on NAFLD Progression in Type 2 Diabetes: The IMAGIN Pilot Study
por: Caturano, Alfredo, et al.
Publicado: (2023)

Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis
por: McIntosh, Brendan, et al.
Publicado: (2011)

Hemichorea-Hemiballism as the First Presentation of Type 2 Diabetes
por: Ray, Sayantan, et al.
Publicado: (2015)

Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes
por: Israel, Marc K, et al.
Publicado: (2008)

The Efficacy and Safety of Imeglimin as Add-on Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy
por: Fouqueray, Pascale, et al.
Publicado: (2013)

SAT-LB030 Efficacy of Combined Therapy with Metformin and Sitagliptin in Patients with Type 2 Diabetes Who Did Not Reach Target Levels of Glycated Hemoglobin on Metformin Monotherapy
por: Klitsunova, Yuliia, et al.
Publicado: (2019)

Does poor glucose control increase the severity and mortality in patients with diabetes and COVID-19?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2020)

Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis
por: Mekuria, Abraham Nigussie, et al.
Publicado: (2019)

Dose distribution and up‐titration patterns of metformin monotherapy in patients with type 2 diabetes
por: Iglay, Kristy, et al.
Publicado: (2019)

Treatment Compliance with Fixed-Dose Combination of Vildagliptin/Metformin in Patients with Type 2 Diabetes Mellitus Inadequately Controlled with Metformin Monotherapy: A 24-Week Observational Study
por: Rombopoulos, Grigorios, et al.
Publicado: (2015)

Effect of metformin monotherapy and dual or triple concomitant therapy with metformin on glycemic control and lipid profile management of patients with type 2 diabetes mellitus
por: Lin, Yan-Yu, et al.
Publicado: (2022)

A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy
por: White, Judith L, et al.
Publicado: (2014)

Should metformin remain the first-line therapy for treatment of type 2 diabetes?
por: Baker, Chelsea, et al.
Publicado: (2021)

Testing the Therapeutic Equivalence of Alogliptin, Linagliptin, Saxagliptin, Sitagliptin or Vildagliptin as Monotherapy or in Combination with Metformin in Patients with Type 2 Diabetes
por: Messori, Andrea, et al.
Publicado: (2014)

Comparison of the Efficacy and Safety of Metformin-Based Combination Therapy Versus Metformin Alone in Children and Adolescents With Type 2 Diabetes Mellitus: A Meta-Analysis
por: Khan, Raza A, et al.
Publicado: (2023)

Bariatric surgery and diabetes remission: Who would have thought it?
por: Singh, Awadhesh Kumar, et al.
Publicado: (2015)

Letter to the editor in response to the article: “Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis (Kumar et al.)”
por: Kumar Singh, Awadhesh, et al.
Publicado: (2020)

Renin-angiotensin system blockers-SGLT2 inhibitors-mineralocorticoid receptor antagonists in diabetic kidney disease: A tale of the past two decades!
por: Singh, Awadhesh Kumar, et al.
Publicado: (2022)

Comparison of Exenatide and Metformin Monotherapy in Overweight/Obese Patients with Newly Diagnosed Type 2 Diabetes
por: Liu, Jia, et al.
Publicado: (2017)

Patterns of metformin monotherapy discontinuation and reinitiation in people with type 2 diabetes mellitus in New Zealand
por: Horsburgh, Simon, et al.
Publicado: (2021)

Colistin monotherapy versus therapy combination
por: Charra, B, et al.
Publicado: (2010)

Fixed-dose combination of sitagliptin and metformin for the treatment of type 2 diabetes
por: Reynolds, Jonathan K
Publicado: (2009)

Metformin Monotherapy Downregulates Diabetes-Associated Inflammatory Status and Impacts on Mortality
por: Tizazu, Anteneh Mehari, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jppe25fm3moll4s4oj7crv2fhu